金吾财讯 | 阿斯利康(AZN)盘前股价下挫,暂跌2.65%,报68.08美元。消息面上,公司将终止针对其前列腺癌治疗药物Truqap的CAPITello-280三期临床试验,原因是该试验不太可能达到双重主要终点。公司周二称,这一决定是在审查了独立数据监测委员会建议的中期分析数据后作出的。该公司表示,与使用多西他赛和雄激素剥夺疗法(ADT)加安慰剂的对照组相比,Truqap联合多西他赛和ADT的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.